Bayer will spend more than $30 million over the next five years to fund joint research projects with Brigham and Women’s Hospital (BWH) and Massachusetts General Hospital (MGH) at a new joint lab opened by the three to research new drug candidates to treat chronic lung diseases.
The new joint lab is designed to combine Bayer’s capabilities in drug discovery and development with complementary clinical expertise, understanding of disease mechanisms, data analysis capabilities, and insights from physician-scientists at MGH and BWH, where the lab is located.
